Table 2.
Comparison of commercially developed anti-CD19 CAR T-cell compounds
| Axicabtagene ciloleucel (KTE019) | Tisagenlecleucel (CTL019) | Lisocabtagene Maraleucel (JCAR017) | |
|---|---|---|---|
| Structure | |||
| Anti-CD19 domain | FCM63 | FCM63 | FCM63 |
| Costimulatory domain | CD28 | 4-1BB | 4-1BB |
| Viral transfection | Gamma-retrovirus | Lentivirus | Lentivirus |
| Target Cells | PMBCs | PMBCs | CD4:CD8 ratio = 1 |
| Phase-II clinical trial | ZUMA-127 | JULIET42 | TRANSCEND43 |
| Patient characteristics | |||
| Indication | DLBCL, tFL, PMBCL Refractory disease: (1) PD or SD to most recent chemotherapy (2) PD or relapse within 12 months after ASCT |
DLBCL, tFL (1) after at least two lines of therapy (2) either relapsed after or ineligible for ASCT |
DLBCL, tFL, PMBCL, FL3b (1) after two lines of treatment (2) MCL after one line of treatment |
| Refractory to last treatment | 74% | 55% | 67% |
| Patients included | 111 | 165 | 134 |
| Patients infused | 101 | 111 | 114 |
| Time from leuka-pheresis/enrolment to reinfusion | 17 days | 54 days | n.a. |
| Efficacy | |||
| Best OR/best CR | OR 82% CR 54% | OR 52% CR 40% | OR 75% CR 55% |
| CR after 6 months | 40% | 29% | 34% |
| Toxicity | |||
| CRS grade 3–5 | 13% | 22% | 1% |
| Tocilizumab usage | 43% | 14% | 12% |
| CRES grade 3–5 | 28% | 12% | 12% |
| Duration of response | 11 months (3.9 months; NR)36 |
NR (181; 527 days) |
NR (5 months; NR) |
Abbreviations: PMBC, peripheral blood mononuclear cells; PD, progressive disease; SD, stable disease; DLBCL, diffuse large B-cell lymphoma; tFL, transformed follicular lymphoma; PMBCL, peripheral mediastinal B-cell lymphoma; FL3b, follicular lymphoma grade 3b; ASCT, autologous stem cell transplantation; OR, overall response; CR, complete response; CRS, cytokine release syndrome; CRES, CAR related encephalopathy syndrome; NR, not reached.